BRIEF REPORT
|
doi:10.20944/preprints202409.1863.v1
Subject:
Medicine And Pharmacology,
Medicine And Pharmacology
Keywords:
Fabry disease; agalsidase beta; quality of life; reduced infusion time; safety; tolerability
Online: 24 September 2024 (05:53:29 CEST)